Geron shares are trading lower. The company announced that the FDA Oncologic Drugs Advisory Committee voted in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.
Portfolio Pulse from Benzinga Newsdesk
Geron's shares are trading lower despite the FDA Oncologic Drugs Advisory Committee voting in favor of the clinical benefit/risk profile of imetelstat for treating transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.
March 15, 2024 | 11:54 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Geron's stock is trading lower even after a positive vote from the FDA Oncologic Drugs Advisory Committee on imetelstat for certain anemia treatments.
Despite the positive news from the FDA committee regarding imetelstat, Geron's shares are trading lower. This could be due to market expectations already pricing in the approval or concerns about the broader marketability and profitability of the treatment. The immediate negative reaction in stock price might not reflect the long-term value of this approval.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100